Guest guest Posted September 24, 2005 Report Share Posted September 24, 2005 For colorectal cancer, it is recommended that carcinoembryonic antigen (CEA) levels be measured preoperatively if it would change surgical management. It is recommended that CEA levels be monitored every 2 to 3 months for 32 years, if resection of liver metastasis would be clinically indicated. The data are insufficient to recommend the routine use of lipid-associated sialic acid (LASA), CA 19-9, DNA index, DNA flow cytometric proliferation analysis, p53 tumor suppressor gene, and ras oncogene. For breast cancer, estrogen receptor and progesterone receptor are recommended to be measured on every primary specimen, but on subsequent specimens only if it would lead to a change in management. The data are insufficient to recommend the routine use of DNA index, DNA flow cytometric proliferation analysis, CA 15-3, CEA, c-erbB-2, p53 or cathepsin-D. In the absence of readily measurable disease, CA 15-3 and CEA levels can be used to document treatment failure. New markers and new evidence will be evaluated by annual update of these guidelines. ... 1997 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer ... J Clin Oncol 14:2843-2877 1996 by American Society of Clinical Oncology. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 24, 2005 Report Share Posted September 24, 2005 For colorectal cancer, it is recommended that carcinoembryonic antigen (CEA) levels be measured preoperatively if it would change surgical management. It is recommended that CEA levels be monitored every 2 to 3 months for 32 years, if resection of liver metastasis would be clinically indicated. The data are insufficient to recommend the routine use of lipid-associated sialic acid (LASA), CA 19-9, DNA index, DNA flow cytometric proliferation analysis, p53 tumor suppressor gene, and ras oncogene. For breast cancer, estrogen receptor and progesterone receptor are recommended to be measured on every primary specimen, but on subsequent specimens only if it would lead to a change in management. The data are insufficient to recommend the routine use of DNA index, DNA flow cytometric proliferation analysis, CA 15-3, CEA, c-erbB-2, p53 or cathepsin-D. In the absence of readily measurable disease, CA 15-3 and CEA levels can be used to document treatment failure. New markers and new evidence will be evaluated by annual update of these guidelines. ... 1997 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer ... J Clin Oncol 14:2843-2877 1996 by American Society of Clinical Oncology. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 24, 2005 Report Share Posted September 24, 2005 For colorectal cancer, it is recommended that carcinoembryonic antigen (CEA) levels be measured preoperatively if it would change surgical management. It is recommended that CEA levels be monitored every 2 to 3 months for 32 years, if resection of liver metastasis would be clinically indicated. The data are insufficient to recommend the routine use of lipid-associated sialic acid (LASA), CA 19-9, DNA index, DNA flow cytometric proliferation analysis, p53 tumor suppressor gene, and ras oncogene. For breast cancer, estrogen receptor and progesterone receptor are recommended to be measured on every primary specimen, but on subsequent specimens only if it would lead to a change in management. The data are insufficient to recommend the routine use of DNA index, DNA flow cytometric proliferation analysis, CA 15-3, CEA, c-erbB-2, p53 or cathepsin-D. In the absence of readily measurable disease, CA 15-3 and CEA levels can be used to document treatment failure. New markers and new evidence will be evaluated by annual update of these guidelines. ... 1997 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer ... J Clin Oncol 14:2843-2877 1996 by American Society of Clinical Oncology. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 24, 2005 Report Share Posted September 24, 2005 My CEA had been running around 6 something when I was having it tested every three months. Since there was not much changes they were not concerned till my pet/ct showed a cancer mass and my CEA jumped to 12.1. I had surgery 1 month ago and the good news is the mass was scar tissue and not cancer again. I forgot to ask the surgeon why it would have jumped to 12.1 and wonder if they took it after surgery or will now. That one mass of scar tissue showed up in 3 Pet scans! I know my smoking makes mine higher but still don't know why it would double. Still working on stopping smoking but it is not easy. I will be asking my regular Dr for the Zyban he has been trying to give me a prescription for. Hil What is considered the usual frequency of CEA test Ive searched for but cannot find anything which gives the usual testing frequency of CEA levels which is the colon cancer tumor marker found in the blood. I think I have hit the angry stage because I cant help wondering that if this test had been performed before every chemo session the rise in Mikes CEA levels would have been noticed earlier. Its as if he suffered the last 6 and all those side effects for nothing. Mikes CEA was 190 before session 1, 50 after session 6 and 243 after session 12 so you can understand why I am angry and uncertain. Mike is starting Oxaliplatin and Erbitux on Monday and I want to find some reference to take to Mikes Onc which might indicate more frequent testing. On the other hand maybe its the norm but need to know. in Spain Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.